The Relabeling Problem: When Your Peptide Vial Lies About Its Origin
Two major legal actions have exposed a massive vulnerability in the peptide supply chain. A Chinese manufacturer on the FDA Green List was caught relabeling semaglutide, and a Utah doctor was indicted for selling relabeled Chinese peptides to 200+ patients.